News Overview
January 28, 2010
January 26, 2010
January 15, 2010
December 7, 2009
December 6, 2009
Treatment of Venous Thromboembolism (VTE):
Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
» more
Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
» more
December 2, 2009
Leading-edge research in science and medicine:
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
» more
1:46 min.
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
» more
3:08 min. 1:46 min.December 1, 2009
Development of new BiTE antibody for treatment of solid tumors:
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
» more
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
» more
November 30, 2009
November 27, 2009
Award for Climate Program project
Bayer receives European environment award for its vehicle fleet
» more
Bayer receives European environment award for its vehicle fleet
» more
November 11, 2009
Extensive program with global lighthouse projects launched:
Bayer strengthens sustainability commitment
» more
1:37 min.
Bayer strengthens sustainability commitment
» more
1:37 min.November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
» more
1:15 min.
Bayer back on the uptrend
» more
1:15 min.October 23, 2009
New prizes from the Bayer Science & Education Foundation:
Bayer Early Excellence in Science Award 2009: EUR 30,000 for young research scientists
» more
Bayer Early Excellence in Science Award 2009: EUR 30,000 for young research scientists
» more
October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
October 9, 2009
Improvement in orders
Bayer MaterialScience AG ends reduced working hours at German sites
» more
Bayer MaterialScience AG ends reduced working hours at German sites
» more
October 9, 2009
September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
September 22, 2009
Leading-edge medical research and development:
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
» more
1:07 min.
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
» more
1:07 min.
more News
Press Newsletter
